Revelation Biosciences (REVB) Competitors $4.24 -0.14 (-3.20%) As of 11:55 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends REVB vs. MBIO, SLRX, THAR, ARTL, OGEN, MAAQ, ALBT, PTIX, CPHI, and SNOAShould you be buying Revelation Biosciences stock or one of its competitors? The main competitors of Revelation Biosciences include Mustang Bio (MBIO), Salarius Pharmaceuticals (SLRX), Tharimmune (THAR), Artelo Biosciences (ARTL), Oragenics (OGEN), Mana Capital Acquisition (MAAQ), Avalon GloboCare (ALBT), Protagenic Therapeutics (PTIX), China Pharma (CPHI), and Sonoma Pharmaceuticals (SNOA). These companies are all part of the "pharmaceutical products" industry. Revelation Biosciences vs. Mustang Bio Salarius Pharmaceuticals Tharimmune Artelo Biosciences Oragenics Mana Capital Acquisition Avalon GloboCare Protagenic Therapeutics China Pharma Sonoma Pharmaceuticals Revelation Biosciences (NASDAQ:REVB) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their community ranking, dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk. Does the media prefer REVB or MBIO? In the previous week, Revelation Biosciences and Revelation Biosciences both had 1 articles in the media. Mustang Bio's average media sentiment score of 1.10 beat Revelation Biosciences' score of 1.00 indicating that Mustang Bio is being referred to more favorably in the news media. Company Overall Sentiment Revelation Biosciences Positive Mustang Bio Positive Which has more volatility and risk, REVB or MBIO? Revelation Biosciences has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500. Comparatively, Mustang Bio has a beta of 1.73, suggesting that its share price is 73% more volatile than the S&P 500. Does the MarketBeat Community prefer REVB or MBIO? Mustang Bio received 139 more outperform votes than Revelation Biosciences when rated by MarketBeat users. Likewise, 64.26% of users gave Mustang Bio an outperform vote while only 63.83% of users gave Revelation Biosciences an outperform vote. CompanyUnderperformOutperformRevelation BiosciencesOutperform Votes3063.83% Underperform Votes1736.17% Mustang BioOutperform Votes16964.26% Underperform Votes9435.74% Is REVB or MBIO more profitable? Mustang Bio's return on equity of 0.00% beat Revelation Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Revelation BiosciencesN/A -193.51% -84.00% Mustang Bio N/A N/A -172.89% Do analysts prefer REVB or MBIO? Mustang Bio has a consensus target price of $100.00, indicating a potential upside of 3,222.26%. Given Mustang Bio's stronger consensus rating and higher possible upside, analysts plainly believe Mustang Bio is more favorable than Revelation Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revelation Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Mustang Bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings and valuation, REVB or MBIO? Mustang Bio is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRevelation BiosciencesN/AN/A-$120K-$268.16-0.02Mustang BioN/AN/A-$51.60M-$78.00-0.04 Do institutionals and insiders hold more shares of REVB or MBIO? 12.8% of Revelation Biosciences shares are owned by institutional investors. Comparatively, 10.0% of Mustang Bio shares are owned by institutional investors. 0.1% of Revelation Biosciences shares are owned by insiders. Comparatively, 0.5% of Mustang Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryMustang Bio beats Revelation Biosciences on 10 of the 14 factors compared between the two stocks. Get Revelation Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for REVB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart REVB vs. The Competition Export to ExcelMetricRevelation BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.18M$7.00B$5.76B$9.08BDividend YieldN/A2.89%5.29%4.00%P/E Ratio-0.0210.2388.5618.43Price / SalesN/A241.85954.0768.32Price / CashN/A22.6637.4433.55Price / Book0.015.375.164.80Net Income-$120,000.00$125.94M$109.04M$223.10M7 Day Performance14.66%7.45%2.96%1.35%1 Month Performance-57.43%4.74%2.95%-0.60%1 Year Performance-89.47%10.82%26.01%23.28% Revelation Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)REVBRevelation Biosciences1.2872 of 5 stars$4.24-3.2%N/A-91.4%$1.15MN/A-0.0210Positive NewsMBIOMustang Bio3.0852 of 5 stars$4.16-13.2%$100.00+2,303.8%-95.4%$3.99MN/A-0.05100Gap DownSLRXSalarius Pharmaceuticals0.1907 of 5 stars$2.46-4.7%N/A-50.9%$3.89MN/A-0.3020THARTharimmune3.1135 of 5 stars$2.01-2.9%$17.00+745.8%-67.5%$3.88MN/A0.002ARTLArtelo Biosciences3.0233 of 5 stars$1.20+1.7%$5.50+358.3%+0.0%$3.88MN/A-0.425Gap DownOGENOragenicsN/A$0.31+0.3%N/AN/A$3.76M$40,000.00-0.045News CoverageGap DownMAAQMana Capital AcquisitionN/A$0.46-8.1%N/A-92.7%$3.73MN/A0.001High Trading VolumeALBTAvalon GloboCare0.6621 of 5 stars$3.39-5.3%N/A-45.2%$3.70M$1.26M-0.175PTIXProtagenic Therapeutics1.5729 of 5 stars$0.51+14.0%N/A-61.0%$3.67MN/A-0.402Gap DownHigh Trading VolumeCPHIChina PharmaN/A$0.19-7.4%N/A-54.5%$3.62M$7.01M0.00250SNOASonoma Pharmaceuticals0.8408 of 5 stars$2.64-7.0%N/A+1,581.4%$3.54M$12.73M-0.53180Earnings ReportUpcoming EarningsNews Coverage Related Companies and Tools Related Companies Mustang Bio Competitors Salarius Pharmaceuticals Competitors Tharimmune Competitors Artelo Biosciences Competitors Oragenics Competitors Mana Capital Acquisition Competitors Avalon GloboCare Competitors Protagenic Therapeutics Competitors China Pharma Competitors Sonoma Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:REVB) was last updated on 2/6/2025 by MarketBeat.com Staff From Our PartnersNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for March 13th. Because on that day, I believe we could see a $2 Trillion shock INTO the...Timothy Sykes | SponsoredA new coin is elbowing its way to the top of the crypto worldWith Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | SponsoredElon’s ‘Agents’ StrikeHe might be the richest man on the planet – but Elon Musk just landed himself a new job... In a move that c...Altimetry | SponsoredElon Musk: The U.S. Dollar is Doomed Unless We ActBillionaire Warren Buffett told CNBC the U.S. dollar is on the path to disaster. And Charles Schwab reports, "...Stansberry Research | SponsoredAmazon coin set to soar 25X – starting January 20thThis tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored“The most important AI company Americans know least about…”If you own a smartphone, there’s a good chance you’re already benefiting from its technology—because it’s on h...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revelation Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revelation Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.